The SEC filings page for OnKure Therapeutics, Inc. (OKUR) provides access to the company’s official regulatory disclosures as a clinical-stage biopharmaceutical issuer listed on the Nasdaq Global Market. These documents offer detailed information about its precision oncology programs, financial condition, and capital markets activities, complementing the high-level descriptions found in press releases.
Through its periodic reports on Forms 10-K and 10-Q, OnKure describes its focus on discovering and developing precision medicines that target biologically validated drivers of cancers underserved by current therapies. These filings expand on the company’s strategy around PI3Kα-targeted programs, including its lead candidate OKI-219 and its PI3Kα pan-mutant and other discovery-stage efforts, and include sections such as “Risk Factors” that outline scientific, clinical, regulatory, and financial risks.
Current reports on Form 8-K capture material events between periodic filings. For example, OnKure has filed 8-Ks to report quarterly financial results and to disclose entry into a sales agreement with Leerink Partners LLC for an at-the-market offering program of its Class A common stock. That agreement allows the company, subject to specified parameters and an effective shelf registration statement on Form S-3, to sell shares through Leerink Partners acting as sales agent, with compensation based on a percentage of gross proceeds.
On this page, users can review new and historical SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and registration statements such as Form S-3 referenced in the at-the-market program. Stock Titan’s tools apply AI-powered summaries to help explain the contents of lengthy filings, highlight key items like clinical development updates, capital raising arrangements, and risk disclosures, and make it easier to track how OnKure’s regulatory narrative evolves over time.
OnKure Therapeutics reported first quarter 2026 results and highlighted a major capital raise and pipeline refocus. Cash and cash equivalents were $192.1 million as of March 31, 2026, including proceeds from an oversubscribed $150 million private placement, which the company expects will fund operations into 2029.
Research and development expenses were $11.7 million and general and administrative expenses were $3.9 million, both slightly lower than the prior-year quarter. Net loss was $15.2 million, or $1.11 per share, compared with $15.9 million, or $1.19 per share, a year earlier.
Strategically, OnKure nominated two next-generation PI3Kα pan-mutant selective inhibitor candidates, OKI-355 for vascular anomalies and OKI-345 for breast cancer, with plans to submit IND applications for both in the first half of 2027. The company is not planning to independently pursue further clinical development of OKI-219 but will report data from the PIKture-01 study by the end of 2026.
OnKure Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing precision small-molecule drugs targeting mutant PI3Kα for cancers and vascular anomalies. It reported a net loss of $15.2 million for the quarter ended March 31, 2026, slightly improved from $15.9 million a year earlier, as research and development expenses decreased to $11.7 million and general and administrative costs held roughly flat at $3.9 million.
A key event was a private placement completed on March 31, 2026, providing approximately $150.0 million in gross proceeds through the sale of 26,713,638 Class A shares at $4.15 per share and 9,430,957 pre-funded warrants at $4.1499 per underlying share. After this financing, cash and cash equivalents rose to $192.1 million from $59.1 million at year-end 2025, and management now believes available cash will fund the current operating plan for at least 12 months.
As of May 4, 2026, there were 40,395,480 Class A shares outstanding, reflecting significant dilution from equity issuances. OnKure is prioritizing next-generation PI3Kα pan-mutant programs OKI-345 and OKI-355, while not planning further independent clinical development of OKI-219. The company continues to operate at a loss and anticipates increased spending as its pipeline progresses.
OnKure Therapeutics, Inc. has filed a shelf registration to permit the resale by selling stockholders of up to 36,144,595 shares of Class A common stock. The shares consist of 26,713,638 outstanding shares and 9,430,957 shares issuable upon exercise of pre-funded warrants issued in a private placement closed March 31, 2026. The company states it will not receive proceeds from resales under this prospectus; however, it will receive proceeds if pre-funded warrants are exercised for cash. The prospectus notes 40,395,480 shares outstanding as of April 1, 2026 and a Beneficial Ownership Limitation tied to pre-funded warrant exercises (default 19.99%).
OnKure Therapeutics, Inc. is asking stockholders to vote at its 2026 virtual annual meeting on director elections, auditor ratification and a major update to its equity plan. Holders of 40,395,480 shares of Class A Common Stock as of April 16, 2026 may vote, one vote per share.
Stockholders will elect three Class II directors (R. Michael Carruthers, Valerie M. Jansen and Edward T. Mathers) to terms ending at the 2029 meeting and vote on ratifying KPMG LLP as independent auditor for the year ending December 31, 2026. The meeting will be held online on June 3, 2026 at 9:00 a.m. Eastern Time.
A key item is approval of an amended and restated 2024 Equity Incentive Plan, which would add 3,231,638 shares (about 8% of outstanding shares) to the plan’s reserve, remove the 2,407,100‑share annual cap in the evergreen provision (after a 1:10 reverse split), and introduce a limit on incentive stock options. The board cites dilution from a March 2026 $150.0 million PIPE financing, in which 26,713,638 shares were sold, and the resulting fall of employee ownership below the 25th percentile of peers, as reasons to expand equity capacity to support recruitment, retention and long‑term incentives.
OnKure Therapeutics, Inc. reported the initial ownership of a major shareholder group led by AI Biotechnology LLC. The filing shows AI Biotechnology holds pre-funded warrants exercisable for 5,640,222 shares of Class A Common Stock at an exercise price of $0.0001 per share, plus 3,998,332 shares of Class A Common Stock.
The pre-funded warrants are subject to a Beneficial Ownership Blocker, limiting exercises so that AI Biotechnology’s beneficial ownership does not exceed 9.99% of outstanding Class A Common Stock, unless increased (with notice) up to but not above 19.99%. Access Industries entities and Len Blavatnik may be deemed indirect beneficial owners but disclaim beneficial ownership beyond their pecuniary interest.
AI Biotechnology LLC and affiliated Access Industries entities report beneficial ownership of 9,091,532 OnKure Therapeutics Class A shares, equal to 19.99% of the class. This includes 3,998,332 shares purchased directly and 5,093,200 shares issuable from pre-funded warrants.
On March 31, 2026, AI Biotechnology bought 3,998,332 shares at $4.15 per share and 5,640,222 pre-funded warrants at $4.1499 each, with a $0.0001 exercise price per share. The warrants are limited by a "Beneficial Ownership Blocker" that generally caps ownership at 9.99%, adjustable up to 19.99% with 61 days’ notice.
AI Biotechnology received a board designation right under a Securities Purchase Agreement, and Dr. Liam Ratcliffe of Access Industries now serves on OnKure’s board, conditioned on AI Biotechnology retaining at least 50% of the purchased securities. Registration rights provide for resale registration of the shares and warrant shares under a future SEC registration statement.
OnKure Therapeutics ownership filing: StepStone entities report shared beneficial ownership of 2,660,612 shares of Class A Common Stock, representing 6.6% of the class. The filing cites 40,395,478 shares outstanding as of April 1, 2026. The report attributes shared voting and dispositive power to StepStone-related partnerships and managers.
OnKure Therapeutics reports that Trails Edge-related filers beneficially own 2,409,638 shares (6.0% of Class A Common Stock) as of March 31, 2026. The filing states those shares are held directly by Trails Edge Biotechnology and that Trails Edge Capital and Ortav Yehudai may be deemed beneficial owners by virtue of management and voting discretion. Ownership percentages are calculated from approximately 40,387,201 shares issued and outstanding as of the Event Date, reflecting 13,673,565 shares outstanding as of March 11, 2026 and 26,713,636 shares issued in a private placement on March 31, 2026. The report is a joint Schedule 13G, and signatures and a Joint Filing Agreement are included.